ESC 23: Hot Line & Late-breaking Science Video Collection

  • Published:  04 August 2023
  • Views: 

    Views Icon

    5460

  • Likes: 

    Heart Icon

    3

Up Next

ESC 23: Hot Line & Late-breaking Science Video Collection

  • Published:  04 August 2023
  • Views: 

    Views Icon

    5460

  • Likes: 

    Heart Icon

    3

Average (ratings)
No ratings
Your rating
About the episode

ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104).

 

The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in patients with heterozygous familial hypercholesterolemia as compared to placebo. 450 participants were enrolled in this randomized, double-blind study, which ran for a duration of 24 weeks. 

 

Questions:

  1. What is the unmet need in patients with Heterozygous Familial Hypercholesterolemia?
  2. What is the mechanism of action of LIB003? How does it compare to other PCSK9 inhibitors?
  3. What is the study design, and what are the baseline characteristics of the patients?
  4. What are the results presented at ESC?
  5. What is the potential impact of these findings?
  6. What are the next steps? What are the remaining knowledge gaps?

 

Recorded on-site at ESC Congress 2023, Amsterdam. 

 

Editors: Mirjam Boros and Jordan Rance

Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles

Overview

What's hot at the European Society of Cardiology (ESC) Congress 2023?

Browse our curated coverage of the latest updates in cardiology from Amsterdam.

  • Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen
  • For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
  • Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
  • We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.

More from this programme

Part 4

Expert Interviews

25 sessions
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now

Part 6

Behind the Heart

23 sessions
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now
Watch now

Faculty Biographies

Frederick Raal

Frederick Raal

Professor and Director of the Carbohydrate and Lipid Metabolism Research Unit

Professor Frederick Raal is a distinguished Professor and the Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. He also serves as the Head of the Division of Endocrinology and Metabolism at the same institution.

He graduated with an MBBCh degree in 1981, followed by a Master of Medicine in 1991, a PhD in 2000, and a Doctor of Science in 2022. Throughout his career, Professor Raal has earned several prestigious postgraduate awards, including the TH Bothwell Research Prize, the FJ Milne Award, and the Vice Chancellor’s Research Award from the University of the Witwatersrand.

He has authored hundreds of original articles and book chapters and served as a reviewer for several leading international journals, including the New England Journal of Medicine, The Lancet, Circulation, and Atherosclerosis. Additionally, he sits on the Editorial Board of Atherosclerosis, co-edits Current Opinion in…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.